(Q40082386)

17 September 2017

1 reference

title

The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations (English)

1 reference

17 September 2017

The prolactin secretory response to neuroleptic drugs: Mechanisms, applications and limitations (English)

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

6 August 2023

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

6 August 2023

author name string

R. T. Rubin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6104835

6 August 2023

S. E. Hays

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6104835

6 August 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6104835

6 August 2023

publication date

1 January 1980

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:0306453080900153?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

https://api.elsevier.com/content/article/PII:0306453080900153?httpAccept=text/plain

6 August 2023

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

6 August 2023

published in

Psychoneuroendocrinology

1 reference

17 September 2017

volume

5

1 reference

17 September 2017

issue

2

1 reference

17 September 2017

page(s)

121-137

1 reference

Prolactin in CSF selectively increases dopamine turnover in the median eminence

17 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Mechanism of Induction of Mammary Differentiation in Sprague-Dawley Female Rats by Perphenazine

6 August 2023

3

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Acute Changes in Blood and Pituitary Prolactin After a Single Injection of Perphenazine

6 August 2023

5

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Effects of cimetidine on prolactin, LH, and sex steroid secretion in male and female volunteers

6 August 2023

6

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Brain homovanillic acid: Regional changes over time with antipsychotic drugs

6 August 2023

8

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Dopamine/neuroleptic receptors in basal hypothalamus and pituitary

6 August 2023

9

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Estrogen potentiation of phenothiazine-induced prolactin secretion in man

6 August 2023

10

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Binding of dopamine to bovine anterior pituitary gland membranes

6 August 2023

12

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Antipsychotic drugs stimulate prolactin release

6 August 2023

14

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Plasma Level Monitoring of Antipsychotic Drugs

6 August 2023

15

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

3H-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus

6 August 2023

16

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Dopamine and Dihydroergocryptine Binding to the Anterior Pituitary and Other Brain Areas of the Rat and Sheep*

6 August 2023

17

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

3HSpiroperidol (Spiperone) Binding to a Putative Dopamine Receptor in Sheep and Steer Pituitary and Stalk Median Eminence*

6 August 2023

18

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Chlorpromazine Plasma Levels and Effects

6 August 2023

19

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Dose equivalence of the antipsychotic drugs

6 August 2023

20

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Effects of Haloperidol on Serum and Pituitary Prolactin and on Hypothalamic PIF in Rats

6 August 2023

22

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Effects of Haloperidol on Serum and Pituitary Prolactin, LH and FSH, and Hypothalamic PIF and LRF

6 August 2023

23

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Effects of drugs that modify brain monoamine concentrations on plasma gonadotropin and prolactin levels in the rat.

6 August 2023

24

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Studies on serum protein binding of haloperidol

6 August 2023

25

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Stimulatory Role for Brain Serotoninergic System on Prolactin Secretion in the Male Rat

6 August 2023

26

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Dopamine receptor sites in the anterior pituitary

6 August 2023

27

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Relation of Plasma Prolactin to Clinical Response in Schizophrenic Patients

6 August 2023

28

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Localization of the site of the haloperidol-induced, prolactin-mediated increase of dopamine turnover in the median eminence: studies in rats with complete hypothalamic deafferentations

6 August 2023

29

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Variability of prolactin response to intravenous and intramuscular haloperidol in normal adult men

6 August 2023

30

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Dopamine and schizophrenia. A therapy revisited and revised

6 August 2023

32

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Possible relationship between glial cells, dopamine and the effects of antipsychotic drugs

6 August 2023

33

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Effects of prolactin and ergot alkaloids on the tubero-infundibular dopamine (DA) neurons.

6 August 2023

34

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence

6 August 2023

35

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat

6 August 2023

36

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Prolactin response to thyrotropin releasing hormone in normal subjects

6 August 2023

37

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Effect of 5-Hydroxytryptophan (5-HTP) on Plasma Prolactin Levels in Man

6 August 2023

38

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Suppression of prolactin and thyrotropin secretion in the rat by antiserum to thyrotropin-releasing hormone

6 August 2023

39

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Participation of serotonin-containing neurons in the suckling-induced rise in plasma prolactin levels in lactating rats.

6 August 2023

40

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Enhanced prolactin inhibition following chronic treatment with haloperidol and morphine

6 August 2023

43

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency

6 August 2023

46

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Serum prolactin and clinical state during neuroleptic treatment and withdrawal

6 August 2023

47

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Haloperidol: Effect of Long-Term Treatment on Rat Striatal Dopamine Synthesis and Turnover

6 August 2023

48

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Influence of dopamine and thyrotropin releasing hormone on the volume of nuclei of prolactin cells in rat adenohypophysis in vitro

6 August 2023

49

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Serotonergic component of neuroleptic receptors

6 August 2023

50

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

The possible role of histamine in the control of prolactin and gonadotropin release

6 August 2023

52

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Effects of perphenazine enanthate injections on prolactin levels in plasma from schizophrenic women and men

6 August 2023

53

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Effects of Serotonin Precursors and Melatonin on Serum Prolactin Release in Rats

6 August 2023

54

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Twenty-four-hour prolactin profiles in normal and disease states: failure of thyroxine to modify prolactin secretion

6 August 2023

55

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Plasma levels of chlorpromazine in schizophrenia; a critical review of the literature

6 August 2023

56

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Predicting individual responses to drug treatment in schizophrenia: a test dose model

6 August 2023

57

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

The Effect of Neuroleptics on Serum Prolactin in Schizophrenic Patients

6 August 2023

59

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

The dopamine hypothesis of schizophrenia: a review

6 August 2023

60

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Clozapine increases rat serum prolactin levels

6 August 2023

61

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Effect of metabolites of chlorpromazine on plasma prolactin levels in male rats

6 August 2023

63

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Stimulation of rat prolactin secretion by indolealkylamine hallucinogens

6 August 2023

64

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

A comparison of the effects of anti-psychotic drugs on pituitary, striatal and limbic system post-synaptic dopamine receptors

6 August 2023

65

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels

6 August 2023

66

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Relationship between prolactin response and antipsychotic effect of thioridazine in psychiatric patients

6 August 2023

69

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

The Effects of Neurally Active Amino Acids on Prolactin Secretion

6 August 2023

70

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

The effects of gamma-aminobutyric acid on prolactin and gonadotropin secretion in the unanesthetized rat

6 August 2023

71

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Thiethylperazine; clinical antipsychotic efficacy and correlation with potency in predictive systems

6 August 2023

73

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Selective neuroendocrine effects of low-dose haloperidol in normal adult men

6 August 2023

74

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Physiologic and clinical effects of chlorpromazine and their relationship to plasma level

6 August 2023

80

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

The possible role of metabolites in therapeutic response to chlorpromazine treatment

6 August 2023

81

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Differential regional development of tolerance to increase in dopamine turnover upon repeated neuroleptic administration

6 August 2023

82

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Isolation of Gamma-Amino Butyric Acid from Pig Hypothalami and Demonstration of its Prolactin Release-Inhibiting (PIF) Activityin VivoandinVitro*

6 August 2023

83

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Anti-schizophrenic drugs—Membrane receptor sites of action

6 August 2023

84

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

The role of catecholamines in the release of anterior pituitary prolactin in vitro

6 August 2023

85

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Thyrotropin releasing hormone (TRH) is not the physiological prolactin releasing factor (PRF) in the male rat

6 August 2023

86

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

The dopamine hypothesis of schizophrenia: focus on the dopamine receptor

6 August 2023

87

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

The effect of antipsychotic drugs and their clinically inactive analogs on dopamine metabolism

6 August 2023

88

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

An anatomy of schizophrenia?

6 August 2023

89

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophysial portal vessel

6 August 2023

90

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Purification of rat prolactin releasing factor by gel filtration

6 August 2023

91

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Thyrotropin releasing hormone: direct evidence for stimulation of prolactin production by pituitary cells in culture

6 August 2023

92

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment

6 August 2023

94

1 reference

https://api.crossref.org/works/10.1016/0306-4530(80)90015-3

6 August 2023

Identifiers

1 reference

17 September 2017

1 reference